Risk of Non-Alcoholic Fatty Liver Disease in Xanthelasma Palpebrarum
Hsuan-Wei Chen,Jung-Chun Lin,Ying-Hsuen Wu,Yi-Lin Chiu
DOI: https://doi.org/10.2147/jir.s305694
IF: 4.5
2021-05-13
Journal of Inflammation Research
Abstract:Hsuan-Wei Chen, 1 Jung-Chun Lin, 1 Ying-Hsuen Wu, 2, 3, * Yi-Lin Chiu 4, * 1 Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan; 2 Department of Ophthalmology, China Medical University Hospital, China Medical University, Taichung City, Taiwan; 3 School of Medicine, College of Medicine, China Medical University, Taichung City, Taiwan; 4 Department of Biochemistry, National Defense Medical Center, Taipei, Taiwan *These authors contributed equally to this work Correspondence: Yi-Lin Chiu Department of Biochemistry, National Defense Medical Center, Taipei, Taiwan Email Ying-Hsuen Wu Department of Ophthalmology, China Medical University Hospital, China Medical University Email Background: Xanthelasma palpebrarum (XP) is a sign of hyperlipidemia and is closely linked to atherosclerosis. Since fatty liver shares similar risk factors with atherosclerosis, we hypothesized that patients with XP are also at risk of non-alcoholic fatty liver disease (NAFLD). Methods: In this retrospective cohort study, 37 patients with XP were compared with sex- and age-matched controls undergoing general health examination. Moreover, demographic information and lipid profiles were compared. The risk of NAFLD was evaluated using the hepatic steatosis and ZJU indices. In addition, we analyzed publicly available RNA sequencing data from the GSE48452 and GSE61260 datasets in the Gene Expression Omnibus database. Findings: Patients with XP had higher scores of hepatic steatosis index (37 ± 1.13 vs 32 ± 0.82, p=0.0006) and ZJU index (38.77 ± 1.0 vs 33.88 ± 0.74, p=0.0002). In addition, they had higher levels of lipid parameters, including total cholesterol, low-density lipoprotein (LDL), and fasting glucose. Among patients with fatty liver, individuals presenting with XP showed higher serum levels of total cholesterol (216 ± 10.4 vs 188.9 ± 7.6, p=0.04), fasting glucose (117.1 ± 6.4 vs 98.3 ± 2.4, p=0.002), and low-density lipoprotein (145.1 ± 8.7 vs 115.6 ± 6.4, p=0.009) than those without XP. In gene expression analysis, individuals presenting with non-alcoholic steatohepatitis showed higher Z scores of xanthelasma than those without non-alcoholic steatohepatitis. Conclusion: Our results suggest that individuals with XP have a higher risk of progression to NAFLD and develop a more severe dyslipidemia. Keywords: xanthelasma, xanthoma, fatty liver, NASH, NAFLD Xanthelasma palpebrarum (XP) is a yellowish plaque usually seen on the eyelid with demarcation, which is associated with dyslipidemia. Approximately 9.1 to 67.9% of patients with XP have dyslipidemia. 1 Therefore, XP not only affects the cosmetic appearance but also serves as a red flag for hyperlipidemia. Hyperlipidemia, defined as elevated low-density lipoprotein cholesterol (LDL) and reduced high-density lipoprotein cholesterol (HDL), is associated with atherosclerosis and cardiovascular diseases, 2 and patients with XP are at risk for premature atherosclerosis. 3 , 4 Furthermore, systematic reviews and meta-analyses have confirmed a higher incidence of atherosclerosis in patients with XP. 5 Despite having a normal lipid profile, patients with XP have a higher incidence of atherosclerosis. 6 , 7 Since fatty liver disease is also a lipid-related disease, we hypothesized that the presence of XP might serve as a predictor of hepatic lipid accumulation. Therefore, in this study, we attempted to assess the risk of developing non-alcoholic fatty liver disease (NAFLD) in patients with XP. XP is more prevalent in women than in men, with peak incidence occurring in the 40- to 50-year-old population group. 8 In contrast, NAFLD is more prevalent in men than in women, and both the incidence and severity of the disease increase with age. 9 Patients with NAFLD have a higher prevalence of obesity and metabolic syndrome; similarly, individuals with obesity, diabetes, dyslipidemia, and metabolic syndrome are at risk for NAFLD. 10 , 11 , 12 In this study, 37 patients with XP were enrolled to evaluate the relationship between various physiological parameters and the percentage of XP patients with NAFLD. In contrast, liver microarray data of GSE48452 and GSE61260 datasets were used to investigate whether patients with NAFLD or non-alcoholic steatoh -Abstract Truncated-
immunology